ASND Share Price Performance
US$253.29
7.91 (3.22%)
19.2% undervalued intrinsic discount
US$313.36
Fair Value
Price US$253.29
AnalystConsensusTarget US$313.36
AnalystLowTarget US$259.95
Fair ValueUS$313.36
Share Pricen/a
Narrative Update • Aug 21
Ascendis Pharma A/S Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 3 Fair Values set on narratives written by author
ASND Community Narratives
AN
Fair Value
·Fair Value US$313.36 19.2% undervalued intrinsic discount
Long Acting TransCon Therapies Will Reshape Rare Endocrine Treatment Over The Coming Years
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value
·Fair Value US$259.95 2.6% undervalued intrinsic discount
Long Term TransCon Pipeline Execution Will Shape Future Cash Flows And Business Durability
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Long Acting TransCon Therapies Will Reshape Rare Endocrine Treatment Over The Coming Years
Ascendis Pharma is betting that its longer-lasting hormone treatments can make it easier for people with rare endocrine and growth disorders to stay on therapy, as new countries and new patient groups open up. The upside hinges on whether doctors and insurers keep embracing its lead medicines and whether its next wave of treatments clears regulators without delays.Read more
AN
US$313.36
19.2% undervalued intrinsic discount
Fair Value
Revenue
38.33% p.a.
Profit Margin
39.61%
Future PE
24.14x
Price in 2029
US$384.55
Long Term TransCon Pipeline Execution Will Shape Future Cash Flows And Business Durability
Ascendis Pharma already sells two long-acting hormone medicines, but the bigger story is whether it can turn early demand and new uses into a durable, three‑product business. If launches, insurance coverage, and new trial results don’t land as hoped, growth could stay slower for longer even as the company keeps investing.Read more
AN
US$259.95
2.6% undervalued intrinsic discount
Fair Value
Revenue
39.4% p.a.
Profit Margin
22.86%
Future PE
34.05x
Price in 2029
US$314
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
ASND: TransCon Platform Execution And Q2 Progress Should Drive Future Upside
Fair Value: US$313.36 19.2% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ASND: Q2 Execution And M&A Interest Will Test Fairly Priced Story
Fair Value: US$259.95 2.6% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Ascendis Pharma A/S Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
- 11.29
- 91.30%
- 70.84%
- 21.0%
About ASND
- Founded
- 2006
- Employees
- 1189
- CEO
- WebsiteView website
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
